Young woman breaks back in four places in holiday hotel balcony fall
Holly Seaford travelled to the Greek island for a holiday with her partner last week before she fell from the high balcony in a freak accident in the early hours of the morning on Wednesday, July 9. The 20-year-old from Ystrad Mynach fractured four vertebrae and is unable to move in hospital while medics struggle to treat her.
Doctors have told her boyfriend Tate Crees, who is with her in Rhodes, that it will be two months before Holly can move again.
READ MORE: Mum fights for life in Tenerife after falling down hotel stairs
READ MORE: Woman dies after getting into difficulty while swimming in river
Tate said: 'She is lying flat in a hospital bed in a back brace unable to move or walk. Doctors have told us it'll be at least six to eight weeks before she can start to regain mobility. This is going to be a very difficult process.'
Holly's sister Briony said the family can't afford to get Holly back to Wales themselves and have asked for support to fundraise for her repatriation.
She said: 'She's in a lot of pain and is bedbound. The last I heard they'd given her paracetamol. They can't effectively look after her there.'
The couple were due to fly back from Rhodes on the day Holly fell from the balcony. Tate said: 'Although the medical care in Greece is good the hospital sadly doesn't have any nursing support available.
'This means Holly is without help for even the most basic daily needs which is having a serious impact on her wellbeing.
'We are desperate to get her home to the UK where she can receive the professional nursing care and rehabilitation she urgently requires.
'But medical repatriation is incredibly expensive, especially as the only way Holly can fly home is on a stretcher. She requires a specialist medical flight with trained staff to monitor her throughout the journey and unfortunately this isn't covered by insurance.'
Some £3,000 has already been raised to support Holly and her family. You can see the fundraiser here.
Get daily breaking news updates on your phone by joining our WhatsApp community here. We occasionally treat members to special offers, promotions and ads from us and our partners. See our Privacy Notice
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 minutes ago
- Medscape
Mindfulness Therapy Aids IBD Patients With Mental Distress
TOPLINE: Mindfulness-based cognitive therapy reduced psychological distress and improved well-being of patients with inflammatory bowel disease (IBD), and it may offer benefits for sleep quality and inflammation. METHODOLOGY: Even in remission, many patients with IBD experience anxiety, depression, fatigue, and poor sleep, which can lower their quality of life, undermine self-care, and drive up healthcare use. Researchers conducted this trial in the Netherlands between July 2021 and May 2022 to strengthen the evidence for the effectiveness of mindfulness-based cognitive therapy in reducing psychological distress in patients with IBD who had been in remission for at least 3 months and experienced at least mild levels of distress. They randomly assigned 142 patients (mean age, 48.6 years; 64.1% women) to receive either mindfulness therapy plus usual treatment (n = 70; intervention group) or only usual treatment (n = 72; control group); the follow-up period lasted 12 months. The mindfulness therapy program included eight weekly group sessions of 2.5 hours, 30-45 minutes of daily home practice, and a 6-hour silent retreat day between sessions six and seven. Usual treatment included pharmacologic and surgical disease control treatments and the prevention of complications. The primary outcome was psychological distress post-intervention (3 months from baseline), measured using the Hospital Anxiety and Depression Scale (HADS) total score. Secondary outcomes included well-being, sleep, self-compassion, mindfulness skills, and disease activity. TAKEAWAY: Patients in the intervention group vs the control group showed reduced psychological distress (Cohen d [d], -0.61) and an improvement in the HADS total score (unstandardized coefficient B, -3.4; P < .001) at 3 months from baseline. The HADS total scores remained lower in the intervention group vs the control group during the entire 12-month follow-up duration. Compared with patients in the control group, those in the intervention group showed improved well-being (d, 0.41) and increases in mindfulness skills (d, 0.46) and self-compassion (d, 0.42). Patients in the intervention group vs the control group had a reduced total sleep time (d, -0.67) but an increased proportion of deep sleep (d, 0.7). No between-group difference was observed in the occurrence of disease flares, but patients in the control group showed a significant reduction in fecal calprotectin levels, an indicator of intestinal inflammation compared with patients in the control group (d, -0.49). IN PRACTICE: 'Our results demonstrate that MBCT [mindfulness-based cognitive therapy] could be a valuable addition to the currently limited number of psychological treatment options for patients with IBD with psychological distress. The group format of MBCT allows for the simultaneous treatment of more patients, potentially making it more cost-effective than individual therapy. Additionally, group therapy provides opportunities for peer support,' the authors of the study wrote. SOURCE: This study, led by Milou M. ter Avest, MD, Department of Psychiatry, Centre for Mindfulness, Radboud University Medical Centre, Nijmegen, the Netherlands, was published online in Inflammatory Bowel Diseases. LIMITATIONS: This study was limited by its unblinded design, risking expectation bias in self-reports. Mindfulness teachers had varied competence levels, which may have introduced bias. The study did not assess sleep disorders such as obstructive sleep apnea, narcolepsy, or restless legs syndrome that may have affected the sleep metrics. Additionally, electroencephalography headbands were not available for all patients, and technical and self-application issues may have led to unusable nights and data loss. DISCLOSURES: This trial was supported by ZonMw (the Netherlands Organisation for Health Research and Development) and the MindMore Foundation. Two authors reported serving on the advisory boards of various pharmaceutical companies, and one of them also reported receiving a grant from Royal DSM. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
32 minutes ago
- Yahoo
Pilots killed in Southend Airport plane crash named
Two pilots killed when a plane crashed at Southend Airport earlier this month have been named. They were captain Danny Marco Franken and first officer Floris Christiaan Rhee, said flight operator Zeusch Aviation. They are believed to be Dutch. The chartered plane, which had taken a patient to the UK for treatment, crashed shortly after take-off at the airport on 13 July. It's thought the patient had been dropped off and the aircraft was heading back to base in the Netherlands. Two passengers, a female nurse and a male doctor, also died. Zeusch Aviation boss Marco Rietvelt said the pilots were "highly skilled". "Their passion for flying was matched by their dedication to their colleagues and the important missions they carried out," said a statement. "We are all deeply shocked and saddened by this tragic loss. "Our priority is to support the families of those lost, as well as our employees, during this incredibly difficult time. "We are also fully committed to assisting the authorities in their ongoing investigation." The nurse who died was named in reports as 31-year-old Maria Fernanda Rojaz Ortiz, originally from Chile, and the doctor was named as German national Dr Matthias Eyl, 46. The UK's Air Accidents Investigation Branch is investigating. Read more from Sky News: John Johnson, who was at the airport with his wife and children, said the Beechcraft Super King Air 200 crashed soon after take off. "It took off and about three or four seconds [later] it started to bank heavily to its left, and then within a few seconds of that happening, it more or less inverted and crashed just head first into the ground," he said. The pilots had waved at his family moments earlier as they taxied the plane to the take-off position, Mr Johnson said. Zeusch Aviation is based at Lelystad Airport in the Netherlands.
Medscape
33 minutes ago
- Medscape
DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo
The FDA rejected a supplemental Biologics License Application (sBLA) for glofitamab-gxbm (Columvi, Genentech) in combination with gemcitabine and oxaliplatin for the second-line treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who are not candidates for autologous stem cell transplant. A complete response letter from the FDA stated that Genentech's phase 3 STARGLO trial did not provide sufficient evidence to support the proposed second-line DLBCL indication for the T cell engaging bispecific antibody in the US, according to a Genentech statement. However, a conditional FDA approval in the third-line or greater setting remains in place. FDA's decision regarding second-line glofitamab aligns with an advisory committee vote in May, which cited a lack of US patient representation in the trial. The Oncologic Drugs Advisory Committee (ODAC) voted 8-1 against recommending approval, as reported by Medscape Medical News . The FDA asked for ODAC review over concerns that nearly half of the STARGLO participants were from Korea, Taiwan, and China, with most of the remaining participants coming from Europe and Australia. Only 25 US patients were included. Outcomes among Asian vs non-Asian patients differed, with a strong trend toward worse overall survival (OS), rates in White patients and patients from Europe and the US, despite a strong overall 0.59 hazard ratio for OS. Similar trends were observed for progression-free survival and complete response rates. At the time, the FDA said the low US enrollment 'limits the agency's ability to assess the applicability of the study results to a US patient population,' and cited additional concerns regarding comparator drugs used in the trial, according to meeting documents. 'While we are disappointed with this outcome, we remain confident in the data supporting the value of Columvi for US patients who have relapsed following initial treatment, and its key role as monotherapy in the third-line setting,' Genentech's Chief Medical Officer and head of Global Product Developments, Levi Garraway, MD, PhD, said in the company statement regarding the sBLA rejection. 'We are committed to bringing Columvi to more people living with lymphoma and are actively exploring its potential in additional treatment settings, including as frontline therapy.' 'For patients with this aggressive form of lymphoma, effective treatment after relapse is paramount,' added Jeremy Abramson, MD, the principle STARGLO investigator and director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, Boston. Abramson stressed that in the STARGLO trial, the glofitamab combination therapy improved OS, which 'could have a positive impact for patients earlier in their treatment journey.' The regimen is currently approved for this indication in more than 35 countries. It is approved in more than 60 countries for third-line or greater treatment of DLBCL, including in the US where the FDA granted accelerated approval in 2023. STARGLO was also intended as a post-marketing confirmatory study to support conversion of the accelerated approval to full approval, Genentech noted. Results were published in 2024 in The Lancet, and 2-year follow-up data showing sustained overall improvements in the primary and secondary endpoints were presented at 2025 American Society of Clinical Oncology Meeting. Genentech said the regimen is currently being investigated in combination with other agents as a first-line treatment for DLBCL in the phase 3 SKYGLO study.
